Bausch Health Announces Patent Lawsuit Against Amneal Pharmaceuticals
- None.
- None.
Insights
The initiation of a lawsuit by Bausch Health against Amneal Pharmaceuticals over the ANDA filing for a generic version of XIFAXAN® brings the complexities of pharmaceutical patent litigation to the forefront. This type of legal action is a common defensive strategy employed by brand-name drug manufacturers to extend market exclusivity and delay the entry of generic competitors. The invocation of the Hatch-Waxman Act, specifically the Paragraph IV Certification, is a critical event as it not only commences the litigation but also imposes a 30-month stay on the FDA's approval of the generic drug, which can significantly impact the market dynamics.
The outcome of such lawsuits can have substantial financial implications for both parties involved. For Bausch Health, a favorable ruling would maintain its monopoly on the sales of XIFAXAN®, preserving significant revenue streams. Conversely, a ruling in favor of Amneal could accelerate market competition, potentially leading to reduced prices and profit margins for Bausch Health. Stakeholders should monitor this legal battle closely, as the final judgment could influence the company's financial health and stock performance.
From a market perspective, the lawsuit between Bausch Health and Amneal Pharmaceuticals is indicative of the broader trend in the pharmaceutical industry where brand-name companies fiercely protect their high-margin products. XIFAXAN® is a key product in Bausch Health's portfolio and the potential introduction of a generic version by Amneal could disrupt market shares. The 30-month stay provides a temporary shield for Bausch Health, but investors should consider the possibility of an earlier settlement, as seen in Bausch's past settlements with Teva, Sandoz and Sun.
It's important to note that while the litigation is a defensive move for Bausch Health, the company's history of settlements suggests a strategic approach to managing generic competition. Settlements often result in a controlled entry of generics at a future date, which allows the original manufacturer to prepare for the revenue impact. The ongoing litigation with Norwich also adds a layer of uncertainty that investors should account for when evaluating Bausch Health's future revenue projections and market strategy.
The financial implications of Bausch Health's patent litigation against Amneal Pharmaceuticals hinge on the potential delay in generic competition for XIFAXAN®. Investors should be aware that Bausch Health's stock might experience volatility as the market reacts to each development in the lawsuit. The company's previous settlements with other generics manufacturers have likely been factored into the stock price to some extent, but the outcome of this new lawsuit could still sway investor sentiment.
Assessing the potential impact on Bausch Health's revenue and earnings, the protection of XIFAXAN®'s patent could mean sustained high-margin sales for the duration of the stay and beyond, if Bausch prevails. However, should Amneal succeed in proving the patents invalid or unenforceable, the introduction of a generic could erode Bausch's market share and profitability. Long-term investors should consider the company's pipeline and ability to innovate beyond XIFAXAN® as a measure of resilience against such patent cliffs.
LAVAL, QC / ACCESSWIRE / April 5, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) along with its gastroenterology business, Salix Pharmaceuticals, Inc., announced that it filed a lawsuit today in the United States District Court for the District of New Jersey against Amneal Pharmaceuticals of New York, LLC, Amneal EU, Limited, Amneal Pharmaceuticals, LLC, Amneal Pharmaceuticals Private Limited, and Amneal Pharmaceuticals, Inc. This lawsuit follows receipt of a Notice of Paragraph IV Certification stating that Amneal submitted an Abbreviated New Drug Application (ANDA) to the U.S. Food and Drug Administration (FDA) seeking approval to market a generic version of XIFAXAN® (rifaximin) 550 mg tablets. Amneal asserts that certain patents listed in the FDA's Orange Book for XIFAXAN® are unenforceable, invalid, and/or not infringed by Amneal's ANDA product. This action formally initiates the litigation process under the Hatch-Waxman Act and triggers a 30-month stay of any potential FDA approval for Amneal's ANDA.
"Bausch Health remains confident in its XIFAXAN® intellectual property and we will continue to defend our XIFAXAN® franchise for the benefit of patients," Thomas J. Appio, CEO, Bausch Health said. "As a leader in gastrointestinal health, protecting our intellectual property is essential to our ability to continue to develop innovative therapies."
Bausch Health has previously received Paragraph IV Certifications for XIFAXAN® (rifaximin) 550 mg tablets from Teva Pharmaceuticals, Sandoz Inc., Sun Pharmaceuticals and Norwich Pharmaceuticals. The Company has since settled the matters with Teva, Sandoz and Sun in September 2018, May 2020 and September 2020, respectively, while litigation with Norwich remains ongoing.
About XIFAXAN
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
About Salix
Salix Pharmaceuticals is one of the largest specialty pharmaceutical companies in the world committed to the prevention and treatment of gastrointestinal diseases. For more than 30 years, Salix has licensed, developed and marketed innovative products to improve patients' lives and arm health care providers with life-changing solutions for many chronic and debilitating conditions. Salix currently markets its product line to U.S. health care providers through an expanded sales force that focuses on gastroenterology, hepatology, pain specialists and primary care. Salix is headquartered in Bridgewater, New Jersey. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company enriching lives through our relentless drive to deliver better health care outcomes. We develop, manufacture and market a range of products primarily in gastroenterology, hepatology, neurology, dermatology, medical aesthetic devices, international pharmaceuticals and eye health, through our controlling interest in Bausch + Lomb. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, HCPs, employees and investors. For more information, visit www.bauschhealth.com and connect with us on LinkedIn.
Forward-looking Statements
This news release may contain forward-looking statements about the future performance of Bausch Health, which may generally be identified by the use of the words "will," "anticipates," "hopes," "expects," "intends," "plans," "should," "could," "would," "may," "believes," "subject to" and variations or similar expressions, including statements about the Company's actions and plans to vigorously defend its intellectual property. These statements are based upon the current expectations and beliefs of management and are subject to certain risks and uncertainties that could cause actual results to differ materially from those described in the forward-looking statements. In particular, Bausch Health can offer no assurance as to the timing of any approval by the FDA of any ANDA or as to the outcome of any patent litigation. Actual results are subject to other risks and uncertainties that relate more broadly to Bausch Health's overall business, including those more fully described in Bausch Health's most recent annual report on Form 10-K and detailed from time to time in Bausch Health's other filings with the U.S. Securities and Exchange Commission and the Canadian Securities Administrators, which factors are incorporated herein by reference.
| Investor Contacts: | Media Contact: | |
| Solebury Strategic Communications | Kevin Wiggins | |
| ir@bauschhealth.com | corporate.communications@bauschhealth.com | |
| (877) 281-6642 (toll free) | (908) 541-3785 |
SOURCE: Bausch Health Companies Inc.
View the original press release on accesswire.com
FAQ
What lawsuit did Bausch Health Companies Inc. and Salix Pharmaceuticals, Inc. file?
What is the Hatch-Waxman Act?
Why did Bausch Health file the lawsuit?
What is the significance of the 30-month stay triggered by the lawsuit?
